文献速递特殊人群用药治疗药物监测与药物基因组学

妊娠期癫痫患者左乙拉西坦群体药代动力学与给药方案优化

Population pharmacokinetics and dosing regimen optimization of levetiracetam in epilepsy during pregnancy.
PubMed 文献 · Br J Clin Pharmacol · 2022-11-04

该研究基于37例妊娠期癫痫患者(WWE)的166个浓度-时间点,建立左乙拉西坦(LEV)群体药代动力学模型,发现表观清除率(CL/F)典型值为3.82 L/h,且总休重(TBW)与妊娠期显著影响CL/F;蒙特卡洛模拟提示应依据TBW和妊娠期个体化给药。

要点

  • 妊娠期LEV的CL/F典型值为3.82 L/h(95%CI 3.283-4.357 L/h)。
  • TBW从55 kg增至65 kg且从孕早期至孕中期时,LEV-CL/F增加42.72%。
  • 建议根据患者TBW和妊娠期个体化调整LEV剂量以达治疗范围。

核心结论

  • 妊娠期癫痫患者LEV药代动力学显著改变,基于体重和妊娠期的个体化给药方案可提高达标概率。

研究设计与样本

  • 回顾性收集37例妊娠期癫痫患者接受LEV治疗的166个浓度-时间点,采用非线性混合效应模型建模,蒙特卡洛模拟优化给药方案。

主要发现

  • 最终模型为一级吸收和消除的一室模型,CL/F典型值3.82 L/h(95%CI 3.283-4.357 L/h),相对标准误7.2%。
  • TBW和妊娠期均与LEV-CL/F显著相关;TBW从55 kg增至65 kg且从孕早期至孕中期时,CL/F增加42.72%。

关键数值与推荐

  • 蒙特卡洛模拟显示LEV给药方案应基于患者TBW和妊娠期个体化,以最大化达到治疗范围的可能性。

临床怎么用

  • 临床可依据妊娠期癫痫患者的TBW和妊娠期调整LEV剂量,并参考群体药代动力学模型进行个体化给药。

局限性

  • 样本量较小(37例患者),需进一步研究验证并优化个体化给药方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The pharmacokinetics of levetiracetam (LEV) significantly changed during pregnancy. It is a great challenge to predict the adjusted doses of LEV to reach the preconception target concentrations. This study aimed to establish a population pharmacokinetic model of LEV in women with epilepsy (WWE) during pregnancy to analyse the factors of pharmacokinetic variability and to develop a model-based individualized dosing regimen. METHODS: A total of 166 concentration-time points from 37 WWE during pregnancy treated with LEV were collected to analyse LEV pharmacokinetics with nonlinear mixed-effects modelling. The dosing regimen was optimized by Monte Carlo simulations based on the final model. RESULTS: The LEV pharmacokinetics in pregnant WWE were best described by a 1-compartment model of first-order absorption and elimination. The population typical value of apparent clearance (CL/F) in the final model was estimated to be 3.82 L/h (95% confidence interval 3.283-4.357 L/h) with a relative standard error of 7.2%. Both total body weight (TBW) and trimester of pregnancy were significantly associated with LEV-CL/F during pregnancy; LEV-CL/F increased by 42.72% when TBW increased from 55 to 65 kg from the first trimester to the second trimester. Monte Carlo simulations showed that dosing regimens for LEV should be individualized based on the patient's TBW and trimester of pregnancy to maximize the likelihood of achieving the therapeutic range. CONCLUSION: This first population pharmacokinetic study of LEV in WWE during pregnancy supports the use of a weight-based and pregnancy-based dosing regimen and can lay a foundation for further optimizing the individualized dosing regimens.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Li Y, Wang ML, Guo Y, et al. Population pharmacokinetics and dosing regimen optimization of levetiracetam in epilepsy during pregnancy. Br J Clin Pharmacol. 2022. PMID: 36260320. doi:10.1111/bcp.15572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。